A pilot study of gene/gene and gene/environment interactions in Alzheimer disease

Clinical Medicine and Research

Volumn 9, Issue 1, 2011, Pages 17-25

  Ghebranious, Nader ^a   Mukesh, Bickol ^b   Giampietro, Philip F ^a,c   Glurich, Ingrid ^a   Mickel, Susan F ^a   Waring, Stephen C ^a   McCarty, Catherine A ^a  

^a MARSHFIELD CLINIC   (United States)

^b ALCON RESEARCH LTD   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

ACE; Alzheimer disease; APOE; Biobank; Body mass index; CYP46; Late onset; OLR1; Smoking

Indexed keywords

APOLIPOPROTEIN E; C REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL 24 HYDROXYLASE; DIPEPTIDYL CARBOXYPEPTIDASE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR; OXYGENASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CIGARETTE SMOKING; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MALE; OBESITY; PILOT STUDY; PULSE PRESSURE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING HABIT;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BLOOD PRESSURE; BODY MASS INDEX; C-REACTIVE PROTEIN; ENVIRONMENT; EPISTASIS, GENETIC; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; PEPTIDYL-DIPEPTIDASE A; PILOT PROJECTS; RISK FACTORS; SCAVENGER RECEPTORS, CLASS E; SMOKING; STEROID HYDROXYLASES; TRIGLYCERIDES;

EID: 79953272286     PISSN: 15394182     EISSN: 15546179     Source Type: Journal    
DOI: 10.3121/cmr.2010.894     Document Type: Article

References (37)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
2. Lehmann DJ, Williams J, McBroom J, Smith AD. Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups. Neuroscience 2001;108:541-554.
3. Narain Y, Yip A, Murphy T, Brayne C, Easton D, Evans JG, Xuereb J, Cairns N, Esiri MM, Furlong RA, Rubinsztein DC. The ACE gene and Alzheimer's disease susceptibility. J Med Genet 2000;37:695-697.
4. Sanchez-Guerra M, Combarros O, Infante J, Llorca J, Berciano J, Fontalba A, Fernandez-Luna JL, Pena N, FernandezViadero C. Case-control study and meta-analysis of low density lipoprotein receptor-related protein gene exon 3 polymorphism in Alzheimer's disease. Neurosci Lett 2001;316:17-20.
5. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278:1349-1356.
6. Kehoe PG, Katzov H, Feuk L, Bennet AM, Johansson B, Wiman B, de Faire U, Cairns NJ, Wilcock GK, Brookes AJ, Blennow K, Prince JA. Haplotypes extending across ACE are associated with Alzheimer's disease. Hum Mol Genet 2003;12:859-867.
7. Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Sleegers K, Prince JA, van Duijn CM, Kehoe PG. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am J Epidemiol 2005;162:305-317.
8. Luedecking-Zimmer E, DeKosky ST, Chen Q, Barmada MM, Kamboh MI. Investigation of oxidized LDL-receptor 1 (OLR1) as the candidate gene for Alzheimer's disease on chromosome 12. Hum Genet 2002;111:443-451.
9. Papassotiropoulos A, Streffer JR, Tsolaki M, Schmid S, Thal D, Nicosia F, Iakovidou V, Maddalena A, Lutjohann D, Ghebremedhin E, Hegi T, Pasch T, Traxler M, Bruhl A, Benussi L, Binetti G, Braak H, Nitsch RM, Hock C. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol 2003;60:29-35.
10. Heininger K. A unifying hypothesis of Alzheimer's disease. III. Risk factors. Hum Psychopharmacol 2000;15:1-70.
11. K. A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events. Rev Neurosci 2000;11 Spec No:213-328.
12. Plassman BL, Breitner JC. Recent advances in the genetics of Alzheimer's disease and vascular dementia with an emphasis on gene-environment interactions. J Am Geriatr Soc 1996;44:1242-1250.
13. Almeida OP, Hulse GK, Lawrence D, Flicker L. Smoking as a risk factor for Alzheimer's disease: contrasting evidence from a systematic review of case-control and cohort studies. Addiction 2002;97:15-28.
14. Lopez-Arrieta JM, Rodriguez JL, Sanz F. Efficacy and safety of nicotine on Alzheimer's disease patients. Cochrane Database Syst Rev 2001:CD001749.
15. Tyas SL, Pederson LL, Koval JJ. Is smoking associated with the risk of developing Alzheimer's disease? Results from three Canadian data sets. Ann Epidemiol 2000;10:409-416.
16. Fratiglioni L, Wang HX. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav Brain Res 2000;113:117-120.
17. Tyas SL, White LR, Petrovitch H, Webster Ross G, Foley DJ, Heimovitz HK, Launer LJ. Mid-life smoking and late-life dementia: the Honolulu-Asia Aging Study. Neurobiol Aging 2003;24:589-596.
18. Austen B, Christodoulou G, Terry JE. Relation between cholesterol levels, statins and Alzheimer's disease in the human population. J Nutr Health Aging 2002;6:377-382.
19. Petanceska SS, DeRosa S, Sharma A, Diaz N, Duff K, Tint SG, Refolo LM, Pappolla M. Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol. J Mol Neurosci 2003;20:395-406.
20. Sparks DL, Lopez J, Connor D, Sabbagh M, Seward J, Browne P; Alzheimer's Disease Cholesterol-Lowering Treatment Team. A position paper: based on observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the Alzheimer's Disease Cholesterol-Lowering Treatment Trial (ADCLT). J Mol Neurosci 2003;20:407-410.
21. Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, McDowell I. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002;156:445-453.
22. McCarty CA, Wilke RA, Giampietro PF, Wesbrook SD, Caldwell MD. Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large population-based biobank. Personalized Medicine 2005;2:49-79.
23. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
24. Halperin E, Eskin E. Haplotype reconstruction from genotype data using Imperfect Phylogeny. Bioinformatics 2004;20:1842-1849.
25. Meng Y, Baldwin CT, Bowirrat A, Waraska K, Inzelberg R, Friedland RP, Farrer LA. Association of polymorphisms in the Angiotensin-converting enzyme gene with Alzheimer disease in an Israeli Arab community. Am J Hum Genet 2006;78:871-877.
26. Bertram L, Parkinson M, Mullin K, Menon R, Blacker D, Tanzi RE. No association between a previously reported OLR1 3' UTR polymorphism and Alzheimer's disease in a large family sample. J Med Genet 2004;41:286-288.
27. Combarros O, Infante J, Llorca J, Berciano J. Genetic association of CYP46 and risk for Alzheimer's disease. Dement Geriatr Cogn Disord 2004;18:257-260.
28. Johansson A, Katzov H, Zetterberg H, Feuk L, Johansson B, Bogdanovic N, Andreasen N, Lenhard B, Brookes AJ, Pedersen NL, Blennow K, Prince JA. Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease. Hum Genet 2004;114:581-587.
29. Kolsch H, Lutjohann D, Ludwig M, Schulte A, Ptok U, Jessen F, von Bergmann K, Rao ML, Maier W, Heun R. Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. Mol Psychiatry 2002;7:899-902.
30. Desai P, DeKosky ST, Kamboh MI. Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease. Neurosci Lett 2002;328:9-12.
31. Golanska E, Hulas-Bigoszewska K, Wojcik I, Rieske P, Styczynska M, Peplonska B, Pfeffer A, Luczywek E, Wasiak B, Gabryelewicz T, Religa D, Chodakowska-Zebrowska M, Barcikowska M, Sobow T, Liberski PP. CYP46: a risk factor for Alzheimer's disease or a coincidence? Neurosci Lett 2005;383:105-108.
32. Ingelsson M, Jesneck J, Irizarry MC, Hyman BT, Rebeck GW. Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease. Neurosci Lett 2004;367:228-231.
33. Kabbara A, Payet N, Cottel D, Frigard B, Amouyel P, Lambert JC. Exclusion of CYP46 and APOM as candidate genes for Alzheimer's disease in a French population. Neurosci Lett 2004;363:139-143.
34. Tedde A, Rotondi M, Cellini E, Bagnoli S, Muratore L, Nacmias B, Sorbi S. Lack of association between the CYP46 gene polymorphism and Italian late-onset sporadic Alzheimer's disease. Neurobiol Aging 2006;27:773.e1-3.
35. Wang F, Jia J. Polymorphisms of cholesterol metabolism genes CYP46 and ABCA1 and the risk of sporadic Alzheimer's disease in Chinese. Brain Res 2007;1147:34-38.
36. Ott A, Slooter AJ, Hofman A, van Harskamp F, Witteman JC, Van Broeckhoven C, van Duijn CM, Breteler MM. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 1998;351:1840-1843.
37. Gorospe EC, Dave JK. The risk of dementia with increased body mass index. Age Ageing 2007;36:23-29.